Next generation dengue vaccines

A review of candidates in preclinical development

Julia Schmitz, John Roehrig, Alan Barrett, Joachim Hombach

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Dengue represents a major public health problem of growing global importance. In the absence of specific dengue therapeutics, strategies for disease control have increasingly focused on the development of dengue vaccines. While a licensed dengue vaccine is not yet available, several vaccine candidates are currently being evaluated in clinical trials and are described in detail in accompanying articles. In addition, there are a large variety of candidates in preclinical development, which are based on diverse technologies, ensuring a continued influx of innovation into the development pipeline. Potentially, some of the current preclinical candidates may become next generation dengue vaccines with superior product profiles. This review provides an overview of the various technological approaches to dengue vaccine development and specifically focuses on candidates in preclinical development.

Original languageEnglish (US)
Pages (from-to)7276-7284
Number of pages9
JournalVaccine
Volume29
Issue number42
DOIs
StatePublished - Sep 23 2011

Fingerprint

Dengue Vaccines
dengue
vaccines
Dengue
Vaccines
Public Health
vaccine development
Clinical Trials
Technology
clinical trials
public health
disease control
therapeutics

Keywords

  • Dengue
  • Dengue vaccines
  • Dengue virus

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Next generation dengue vaccines : A review of candidates in preclinical development. / Schmitz, Julia; Roehrig, John; Barrett, Alan; Hombach, Joachim.

In: Vaccine, Vol. 29, No. 42, 23.09.2011, p. 7276-7284.

Research output: Contribution to journalArticle

Schmitz, Julia ; Roehrig, John ; Barrett, Alan ; Hombach, Joachim. / Next generation dengue vaccines : A review of candidates in preclinical development. In: Vaccine. 2011 ; Vol. 29, No. 42. pp. 7276-7284.
@article{20d136d548da4777b1b387c25d0dec0f,
title = "Next generation dengue vaccines: A review of candidates in preclinical development",
abstract = "Dengue represents a major public health problem of growing global importance. In the absence of specific dengue therapeutics, strategies for disease control have increasingly focused on the development of dengue vaccines. While a licensed dengue vaccine is not yet available, several vaccine candidates are currently being evaluated in clinical trials and are described in detail in accompanying articles. In addition, there are a large variety of candidates in preclinical development, which are based on diverse technologies, ensuring a continued influx of innovation into the development pipeline. Potentially, some of the current preclinical candidates may become next generation dengue vaccines with superior product profiles. This review provides an overview of the various technological approaches to dengue vaccine development and specifically focuses on candidates in preclinical development.",
keywords = "Dengue, Dengue vaccines, Dengue virus",
author = "Julia Schmitz and John Roehrig and Alan Barrett and Joachim Hombach",
year = "2011",
month = "9",
day = "23",
doi = "10.1016/j.vaccine.2011.07.017",
language = "English (US)",
volume = "29",
pages = "7276--7284",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "42",

}

TY - JOUR

T1 - Next generation dengue vaccines

T2 - A review of candidates in preclinical development

AU - Schmitz, Julia

AU - Roehrig, John

AU - Barrett, Alan

AU - Hombach, Joachim

PY - 2011/9/23

Y1 - 2011/9/23

N2 - Dengue represents a major public health problem of growing global importance. In the absence of specific dengue therapeutics, strategies for disease control have increasingly focused on the development of dengue vaccines. While a licensed dengue vaccine is not yet available, several vaccine candidates are currently being evaluated in clinical trials and are described in detail in accompanying articles. In addition, there are a large variety of candidates in preclinical development, which are based on diverse technologies, ensuring a continued influx of innovation into the development pipeline. Potentially, some of the current preclinical candidates may become next generation dengue vaccines with superior product profiles. This review provides an overview of the various technological approaches to dengue vaccine development and specifically focuses on candidates in preclinical development.

AB - Dengue represents a major public health problem of growing global importance. In the absence of specific dengue therapeutics, strategies for disease control have increasingly focused on the development of dengue vaccines. While a licensed dengue vaccine is not yet available, several vaccine candidates are currently being evaluated in clinical trials and are described in detail in accompanying articles. In addition, there are a large variety of candidates in preclinical development, which are based on diverse technologies, ensuring a continued influx of innovation into the development pipeline. Potentially, some of the current preclinical candidates may become next generation dengue vaccines with superior product profiles. This review provides an overview of the various technological approaches to dengue vaccine development and specifically focuses on candidates in preclinical development.

KW - Dengue

KW - Dengue vaccines

KW - Dengue virus

UR - http://www.scopus.com/inward/record.url?scp=80052408375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052408375&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2011.07.017

DO - 10.1016/j.vaccine.2011.07.017

M3 - Article

VL - 29

SP - 7276

EP - 7284

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 42

ER -